Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients

References

• Kenemans P, Bast R, Yedima C, Price M, Hilgers J. CA 125 and polymorphic epithelial mucin as serum tumor markers. Cancer Rev 1988; 11: 119–144
   Google Scholar
• Zeillemaker A M, Verbrugh H A, Hoynck van Papendrecht A AGM, Leguit P. CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 1994; 47: 263–265
   PubMed Web of Science ®Google Scholar
• Brioschi P A, Bischof P, Rapin C, De Roten M, Irion O, Krauer F. Longitudinal study of CEA and CA 125 in ovarian cancer. Gynecol Oncol 1985; 21: 1–6
   PubMed Web of Science ®Google Scholar
• Cruickshank D J, Terry P B, Fullerton W T. CA 125-response assessment in epithelial ovarian cancer. Int J Cancer 1992; 51: 58–61
   PubMed Web of Science ®Google Scholar
• Haga Y, Sakamoto K, Egami H, Yoshimura R, Mori K, Akagi M. Clinical significance of serum CA 125 values in patients with cancers of the digestive system. Am J Med Sci 1986; 292: 30–34
   PubMed Web of Science ®Google Scholar
• Simsek H, Kadayifci A, Okan E. Importance of serum CA 125 levels in malignant peritoneal mesothelioma. Tumour Biol 1996; 17: 1–4
   PubMed Web of Science ®Google Scholar
• Kimura Y, Fujii T, Hamamoto K, Miyagawa N, Kataoka M, Iio A. Serum CA 125 level is a good prognostic indicator in lung cancer. Br J Cancer 1990; 62: 676–678
   PubMed Web of Science ®Google Scholar
• Haga Y, Sakamoto K, Egami H, Yoshimura R, Akagi M. Elevation of serum CA 125 values in healthy individuals and pregnant women. Am J Med Sci 1986; 292: 25–29
   PubMed Web of Science ®Google Scholar
• Imai A, Itoh T, Niwa K, Tamaya T. Elevated CA 125 serum levels in a patient with tuberculous peritonitis. Arch Gynecol Obstet 1991; 248: 157–159
   PubMed Web of Science ®Google Scholar
• Bairey O, Blickstein D, Stark P, Prokocimer M, Nativ H M, Kirgner I, et al. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 1733–1738
   PubMed Web of Science ®Google Scholar
• Dilek I, Ayakta H, Demir C, Meral C, Ozturk M. CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol 2005; 27: 51–55
   PubMedGoogle Scholar
• Pabst Th, Ludwig Ch. CA 125: a tumor marker in Non-Hodgkin's lymphomas?. J Clin Oncol 1995; 13: 1827–1828
   PubMed Web of Science ®Google Scholar
• Ravoet Ch, Dargent J L, Le Moine W, Feremans W. CA 125 in primary mediastinal B-cell lymphoma with sclerosis. J Clin Oncol 1995; 13: 530
   PubMed Web of Science ®Google Scholar
• Kubonishi I, Bandobashi K, Murata N, Daibata M, Ido E, Sonobe H. High serum levels of CA 125 and interleukin-6 in a patient with Ki-1 lymphoma. Br J Haematol 1997; 98: 450–452
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Klersy C, Astori C, Brusamolino E, Corso A. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma. Correlation with tumor parameters and disease activity. Cancer 1998; 82: 576–582
   PubMed Web of Science ®Google Scholar
• Ozguroglu M, Turna H, Demir, Doventas A, Demirelli F, Mandel N M. Usefulness of the epithelial tumor marker CA 125 in Non-Hodgkin's lymphoma. Am J Clin Pathol 1999; 22: 615–618
   Web of Science ®Google Scholar
• Kutlik T, Varan A, Erbas B, Buyukpamukeu M. Serum CA 125 levels in children with Non-Hodgkin's Lymphoma. Pediatr Hematol Oncol 1999; 16: 311–319
   PubMed Web of Science ®Google Scholar
• Vlasveld L T, Ermens A A, Sonnenberg A A, Pauwels P. Elevated serum concentrations due to expression by a diffuse large B-cell lymphoma. Anns Clin Biochem 2000; 37: 545–548
   PubMed Web of Science ®Google Scholar
• Benboubker L, Valat C, Linassier C, Cartron G, Delain M, Bout M. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA 125 and LDH serum levels. Ann Oncol 2000; 11: 1485–1491
   PubMed Web of Science ®Google Scholar
• Zidan J, Hussein O, Basher W, Zohar S. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hogkin's lymphoma. Oncologist 2004; 9: 417–421
   PubMed Web of Science ®Google Scholar
• Morra E. The biological markers of non-hodgkin's lymphoma: their role in diagnosis, prognostic assessment and therapeutic strategy. Int J Biol Markers 1999; 14: 149–153
   PubMed Web of Science ®Google Scholar
• Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from multiple myeloma patient. J Immunol 1994; 153: 2102–2109
   PubMed Web of Science ®Google Scholar
• World Health Organization. Classification of neoplastic diseases of hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November, 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Zacharos I D, Efstathiou S P, Petreli E, Geiorgiou G, Tsioulos D I, Mastorantonakis S E. The prognostic significance of CA 125 in patients with non-Hodgkin lymphoma. Eur J Haematol 2002; 69: 221–226
   PubMed Web of Science ®Google Scholar
• Burney I A, Siddiqui T, Siddiqi I. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma. Correlation with tumor parameters and disease activity. Cancer 1999; 85: 755–756
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Federico M, Vítolo U, Zinzani P L, Chisesi T, Clò V, Bellesi G. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Blood 2000; 95: 783–789
   PubMed Web of Science ®Google Scholar
• Avilés A, Zepeda G, Díaz-Maqueo J C, Rodríguez L, Guzman R, García E L. Beta 2 microglobulin level as an indicator of prognosis in diffuse large cell lymphoma. Leuk Lymphoma 1992; 7: 135–138
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E. Prognostic factors in large-cell lymphomas. Leuk Lymphoma 1993; 10(Suppl)57–60
   PubMedGoogle Scholar
• Johnson P W, Whelan J, Longhurst S, Stepniewska K, Matthews J, Ames J. Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. Br J Cancer 1993; 67: 792–797
   PubMed Web of Science ®Google Scholar